An interventional study of Intervention of prevention in Vascular Disease, Cardiovascular and Atrial Fibrillation (AF), sponsored by Assistance Publique Hopitaux De Marseille. Active, not recruiting at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-10.
Sponsored by Assistance Publique Hopitaux De Marseille · Not applicable, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 70 studies in Vascular Diseases with a site in France — 11 open to participants now, 19 under way, 4 of them phase 3. Vascular Diseases · France.
Among the 70 studies in Vascular Diseases with a site in France, this one is the 25th largest by planned enrollment of the 43 interventional ones that give a count, is one of 2 that started in 2024, is one of 28 with no phase, reaches primary completion later than 4 of the 18 other live ones, and was the 65th registered.
694 studies on the registry are indexed under Vascular Diseases; 127 are open to participants now.
Browse Vascular Diseases studies →11 of the 70 studies in Vascular Diseases with a site in France are open now. Recruiting first, the newest first:
CHU de Reims · Sites in France
Ages 18+
Teleflex · Sites in France, United States, Latvia and 1 more country
Ages 18–80
W.L.Gore & Associates · Sites in France, United States, Denmark and 7 more countries
Ages 18+
Phenox GmbH · Sites in France
Ages 18+
University of Melbourne · Sites in France, Australia, Brazil
Ages 18+
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 95 Vascular Diseases studies recruiting now, 59 (62%) set no upper age limit and 13 (14%) stop at 75 or younger; 8 take children under 18; 14 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
70 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 3 · Phase 3 9 · Phase 4 5
First in 2003; this study’s year is marked. 2 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 157 is above the median of 96 across 419 interventional studies indexed under Vascular Diseases.
Median enrollment 281 across the 43 interventional studies, 348 across the 27 observational. Of the 47 that completed or were terminated, 8 (17%) have results posted.
This tab as a report to print or save as PDF → With an account.
33 of 70 have an industry lead sponsor. The 10 most frequent:
Assistance Publique Hopitaux De Marseille is the lead sponsor of 702 studies on the registry; 139 are open to participants now.
Assistance Publique Hopitaux De Marseille has 2 studies filed under Vascular Diseases — fewer than ten, so there is no comparison to draw.
1 of the studies in Vascular Diseases with a site in France that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03683186Phase 3United TherapeuticsA Study Evaluating the Long-Term Efficacy and Safety of Ralinepag in Subjects With PAH Via an Open-Label Extension | 2026-12 |
Add it to your calendar (.ics) → With an account.
Among the 70 studies in Vascular Diseases with a site in France, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
A preventive, multidisciplinary primary care intervention organized around a therapeutic garden: Acceptability to patients suffering from cardio-neurovascular pathology and to those involved in the action.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A 6-month multidisciplinary preventive intervention for each patient: gardening, adapted physical activity, nutritional workshops and questionnaries
Other: Intervention of prevention
Refuse the intervention and answers questionnaries about why
A 6-month multidisciplinary preventive intervention for each patient: gardening, adapted physical activity, nutritional workshops.
Acceptance rate of intervention
Assessing the acceptability of a multidisciplinary intervention combining gardening activities, APA and nutrition workshops, organized around a therapeutic garden, by patients suffering from cardio-neurovascular pathologies and the interveners of the action.
Time frame: From enrollment to the end of treatment at 6 months
Identification of the obstacles and facilitators for intervention
Identify the obstacles and factors facilitating patients' initial adhesion to and commitment to the scheme, and those influencing the implementation of the action by those involved, i.e. the facilitators and caregivers involved.
Time frame: From enrollment to the end of treatment at 6 months
Assessing the impact of the intervention
Assess the impact of the intervention on quality of life, adoption of new lifestyle habits (PA and Mediterranean diet), depressive symptoms and physical performance, taking into account any adverse effects.
Time frame: From enrollment to the end of treatment at 6 months
Plan to share: Undecided
No publications or documents are linked to this record.
Ran from Apr 2024 to primary completion in Mar 2026, 23 months.
Of 104 non-industry interventional studies with no phase under Vascular Diseases, half reached primary completion within 30 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 57. This study's 23 months is below that.
Counting every sponsor, half of 148 studies reached it within 33 months; a quarter within 19 and three quarters within 57.
Completion moved once since we started tracking on Sep 25, 2026: Oct 2026 → Oct 2027, on Nov 10, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Assistance Publique Hopitaux De Marseille →